



TISCO Genomic Revolution Fund (TGENOME)

As of 30 June 2021

Fund Risk Level: Level 7 High Risk

General Information

Fund Type : Equity Foreign Investment Fund (Feeder Fund),
Healthcare Sector Fund

AIMC Category : Health Care

Registered Date : 13 January 2021

Subscription & Redemption Period : Every working day
during 8:30 - 15:00

Minimum Amount for Subscription : 1,000 Baht

Minimum Amount for Redemption : None

Settlement Day : T+4 (after the redemption date)

Dividend Policy : None

Investment Policy

The fund shall invest at least 80% of its NAV in ARK Genomic Revolution ETF (master fund), an actively-managed ETF listed and traded on the New York Stock Exchange, USA. The master fund is managed by ARK Investment Management LLC and will invest under normal circumstances primarily (at least 80% of its assets) in USA and foreign equity securities of companies that are relevant to the Fund's investment theme of Genomic Revolution. Genomic Revolution Companies are companies that the Adviser believes are substantially focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments, improvements and advancements in genomics into their business, such as by offering new products or services that rely on genomic sequencing, analysis, synthesis or instrumentation. These companies may include ones across multiple sectors, such as healthcare, information technology, materials, energy and consumer discretionary. These companies may also develop, produce, manufacture or significantly rely on or enable bionic devices, bio-inspired computing, bioinformatics, molecular medicine and agricultural biotechnology.

The fund may invest in derivatives for hedging purpose, depending on the discretion of the management company as appropriate to the circumstances of each moment. Currently, the fund will invest in derivatives for hedging foreign exchange rate risk about 90% of the foreign investment assets.

Fees and Expenses

• Fee Charged to the Fund (% p.a. of NAV)

Management Fee	1.0700%
Trustee Fee	0.0288900%
Registrar Fee	0.171200%

• Fee Charged to Unit holders (% of investment unit value)

Front-end Fee	1.00%
Back-end Fee	0.15%
Switching In Fee	None
Switching Out Fee	None


Note: The fees and expenses charged above include VAT, specific business tax or any other taxes related with fees and expenses.

Warnings & Recommendation

- Investment contains some degree of risks. The investor should study the fund's prospectus before investing.
- The fund has specific investment in healthcare sector, so it may have risk and price volatility higher than general mutual funds with diversification in several industries. Investors should study the healthcare sector information for investment decisions.
- The fund does not have fully hedging policy against foreign exchange rate, therefore, it may have opportunity loss or receive additional gain from a decrease or an increase in foreign exchange rate and investors may receive redemption proceeds less than their initial investment amount.
- The Management Company reserves the right to reject or halt the subscription order, allocation and/or transferring of investment units whether directly or indirectly for US citizen.

Details of Portfolio

Assets Allocation



Top 5 Holding (By Company)

Securities/Issuer	Proportion
ARK GENOMIC REVOLUTION ETF	101.29%

Remarks: The information is as of June 30, 2021. Current information can be found on the website www.tiscoasset.com

Past Performance of ARK Genomic Revolution ETF

FUND PERFORMANCE

For periods ended June 30, 2021

	3 Months	YTD	1 Year	3 Years	5 Years	Since Inception
• ARKG NAV	4.55%	-0.76%	79.12%	50.03%	42.54%	27.20%
• ARKG Market Price	4.25%	-0.81%	78.83%	50.00%	42.61%	27.19%
NASDAQ Biotech. Index (XNBI)	9.15%	8.55%	20.52%	14.90%	14.44%	8.41%
S&P 500 Index (SPX)	8.55%	15.25%	40.79%	18.67%	17.65%	14.43%
MSCI World Index (MIWO)	7.74%	13.05%	39.04%	14.99%	14.83%	11.13%

Remarks: The information is as of June 30, 2021.

Fund Performance (%)

	Past Performance and Benchmark Return													
	%						% p.a.							
	Year to Date	3 Months	Percentile	6 Months	Percentile	1 Year	Percentile	3 Years	Percentile	5 Years	Percentile	10 Years	Percentile	Since Inception
Fund Return	n.a.	4.29%	95th	n.a.		n.a.		n.a.		n.a.		n.a.		-14.05%
Benchmark Return	n.a.	6.81%	75th	n.a.		n.a.		n.a.		n.a.		n.a.		-6.48%
Benchmark Return (Hedging)	n.a.	4.50%	95th	n.a.		n.a.		n.a.		n.a.		n.a.		-10.79%
Fund Standard Deviation	n.a.	33.97%	95th	n.a.		n.a.		n.a.		n.a.		n.a.		41.38%
Benchmark Standard Deviation	n.a.	26.64%	95th	n.a.		n.a.		n.a.		n.a.		n.a.		33.79%

Benchmark: Master fund's performance, calculating in THB term

Remarks: The information is as of June 30, 2021.